• 1
    Kovar H. Progress in the molecular biology of Ewing tumors. Sarcoma. 1998; 2: 3-17.
  • 2
    Lawlor ER, Lim JF, Tao W, et al. The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. Cancer Res. 1998; 58: 2469-2476.
  • 3
    Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin. 1972; 22: 95-98.
  • 4
    Jaffe N, Paed D, Traggis D, Salian S, Cassady JR. Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer. 1976; 38: 1925-1930.
  • 5
    Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-EWING 99 clinical trial. Pediatr Blood Cancer. 2006; 47: 22-29.
  • 6
    Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004; 22: 2873-2876.
  • 7
    Perlman EJ, Dickman PS, Askin FB, Grier HE, Miser JS, Link MP. Ewing's sarcoma—routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Hum Pathol. 1994; 25: 304-307.
  • 8
    Zucker JM, Henry-Amar M. Therapeutic controlled trial in Ewing's sarcoma. Report on the results of a trial by the Clinical Cooperative Group on Radio- and Chemotherapy of the EORTC. Eur J Cancer. 1977; 13: 1019-1023.
  • 9
    Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694-701.
  • 10
    Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in nonmetastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol. 2006; 45: 469-475.
  • 11
    Aparicio J, Munarriz B, Pastor M, et al. Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution. Oncology. 1998; 55: 20-26.
  • 12
    Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000; 18: 4-11.
  • 13
    Sluga M, Windhager R, Lang S, et al. A long-term review of the treatment of patients with Ewing's sarcoma in 1 institution. Eur J Surg Oncol. 2001; 27: 569-573.
  • 14
    Smorenburg CH, van Groeningen CJ, Meijer OW, Visser M, Boven E. Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in the Netherlands. Neth J Med. 2007; 65: 132-136.
  • 15
    Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol. 1997; 15: 2611-2621.
  • 16
    Fraumeni JFJr, Glass AG. Rarity of Ewing's sarcoma among US Negro children. Lancet. 1970; 1: 366-367.
  • 17
    Li FP, Tu JT, Liu FS, Shiang EL. Rarity of Ewing's sarcoma in China [letter]. Lancet. 1980; 1: 1255.
  • 18
    Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer. 1993; 53: 371-376.
  • 19
    Cheung MC, Perez EA, Molina MA, et al. Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg. 2008; 12: 731-738.
  • 20
    Gutierrez JC, De Oliveira LO, Perez EA, Rocha-Lima C, Livingstone AS, Koniaris LG. Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coll Surg. 2007; 205: 479-491; quiz 524.
  • 21
    Gutierrez JC, Perez EA, Franceschi D, Moffat FLJr, Livingstone AS, Koniaris LG. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res. 2007; 141: 105-114.
  • 22
    Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005; 19: 1610-1612.
  • 23
    Lee DJ, Voti L, Mackinnon J, et al. Gender- and race-specific comparison of tobacco-associated cancer incidence trends in Florida with SEER regional cancer incidence data. Cancer Causes Control. 2008; 19: 711-723.
  • 24
    Perez EA, Gutierrez JC, Jin X, et al. Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg. 2007; 11: 114-125.
  • 25
    Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006; 202: 623-629.
  • 26
    Esiashvili N, Goodman M, Marcus RBJr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance, Epidemiology, and End Results data. J Pediatr Hematol Oncol. 2008; 30: 425-430.
  • 27
    Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40( 8 suppl ): IV-19-IV-25.
  • 28
    Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002; 40( 8 suppl ): IV-43-IV-8.
  • 29
    Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002; 40( 8 suppl ): IV-75-IV-81.
  • 30
    Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2003; 8: 541-552.
  • 31
    Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007; 12: 20-37.
  • 32
    Merrill RM, Dearden KA. How representative are the Surveillance, Epidemiology, and End Results (SEER) program cancer data of the United States? Cancer Causes Control. 2004; 15: 1027-1034.
  • 33
    Petrelli NJ. SEER data: it can be thought provoking, but where do we go from here? Ann Surg Oncol. 2007; 14: 2173-2174.
  • 34
    Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002; 40( 8 suppl ): IV-62-IV-68.
  • 35
    Schrag D, Bach PB, Dahlman C, Warren JL. Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care. 2002; 40( 8 suppl ): IV-96-IV-103.
  • 36
    Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40( 8 suppl ): IV-49-IV-54.
  • 37
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40( 8 suppl ): IV-55-IV-61.
  • 38
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl ): IV-3-IV-18.
  • 39
    Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003; 14: 175-193.
  • 40
    National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Program. SEER 17 Registries Limited-Use Data (2000-2006). Bethesda, Md: National Cancer Institute, Division of Cancer and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; based on the November 2008 submission.
  • 41
    World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000. Available at: Accessed December 30, 2008.
  • 42
    GreeneFL, PageDL, FlemingID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
  • 43
    National Cancer Institute. SEER Summary Staging Manual. Available at: Accessed December 30, 2008.
  • 44
    National Cancer Institute. SEER Standard Population Data. Available at: Accessed December 30, 2008.
  • 45
    National Cancer Institute. SEER Cancer Statistics Review, 1973-2005. Available at: Accessed December 30, 2008.
  • 46
    Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 2007; 459: 40-47.
  • 47
    Cope JU. A viral etiology for Ewing's sarcoma. Med Hypotheses. 2000; 55: 369-372.
  • 48
    Kebudi R, Bilgic B, Gorgun O, Ayan I, Demiryont M. Is the Epstein-Barr virus implicated in Ewing sarcoma? Med Pediatr Oncol. 2003; 40: 256-257.
  • 49
    Valery PC, McWhirter W, Sleigh A, Williams G, Bain C. A national case-control study of Ewing's sarcoma family of tumours in Australia. Int J Cancer. 2003; 105: 825-830.
  • 50
    Argon A, Basaran M, Yaman F, et al. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. Jpn J Clin Oncol. 2004; 34: 667-672.
  • 51
    Daugaard S, Sunde LM, Kamby C, Schiodt T, Jensen OM. Ewing's sarcoma. A retrospective study of prognostic factors and treatment results. Acta Oncol. 1987; 26: 281-287.
  • 52
    Delepine N, Delepine G, Cornille H, Voisin MC, Brun B, Desbois JC. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. J Chemother. 1997; 9: 352-363.
  • 53
    Gehan EA, Nesbit MEJr, Burgert EOJr, et al. Prognostic factors in children with Ewing's sarcoma. Natl Cancer Inst Monogr. 1981; 56: 273-278.
  • 54
    Gobel V, Jurgens H, Etspuler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987; 113: 187-191.
  • 55
    Luksch R, Sampietro G, Collini P, et al. Prognostic value of clinicopathologic characteristics including neuroectodermal differentiation in osseous Ewing's sarcoma family of tumors in children. Tumori. 1999; 85: 101-107.
  • 56
    Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001; 85: 1646-1654.
  • 57
    O'Connor MI, Pritchard DJ. Ewing's sarcoma. Prognostic factors, disease control, and the reemerging role of surgical treatment. Clin Orthop Relat Res. 1991; 262: 78-87.
  • 58
    Pomeroy TC, Johnson RE. Prognostic factors for survival in Ewing's sarcoma. Am J Roentgenol Radium Ther Nucl Med. 1975; 123: 598-606.
  • 59
    Sailer SL, Harmon DC, Mankin HJ, Truman JT, Suit HD. Ewing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys. 1988; 15: 43-52.
  • 60
    Sauer R, Jurgens H, Burgers JM, Dunst J, Hawlicek R, Michaelis J. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol. 1987; 10: 101-110.
  • 61
    Craft AW, Cotterill S, Imeson J. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide: a UKCCSG/MRC study. Am J Pediatr Hematol Oncol. 1993; 15: S31-S35.
  • 62
    Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008; 20: 412-418.
  • 63
    Scurr M, Judson I. How to treat the Ewing's family of sarcomas in adult patients. Oncologist. 2006; 11: 65-72.
  • 64
    Scully SP, Temple HT, O'Keefe RJ, Scarborough MT, Mankin HJ, Gebhardt MC. Role of surgical resection in pelvic Ewing's sarcoma. J Clin Oncol. 1995; 13: 2336-2341.
  • 65
    Dunst J, Jurgens H, Sauer R, et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995; 32: 919-930.
  • 66
    Hayes FA, Thompson EI, Meyer WH, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol. 1989; 7: 208-213.
  • 67
    Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988; 61: 23-32.
  • 68
    Mendenhall CM, Marcus RBJr, Enneking WF, Springfield DS, Thar TL, Million RR. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer. 1983; 51: 913-917.
  • 69
    Hu HM, Zielinska-Kwiatkowska A, Munro K, et al. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells. J Orthop Res. 2008; 26: 886-893.
  • 70
    Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008; 68: 2176-2185.
  • 71
    Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene. 2001; 20: 5747-5754.
  • 72
    Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol. 2003; 56: 96-102.
  • 73
    Kojima T, Asami S, Chin M, Yoshida Y, Mugishima H, Suzuki T. Detection of chimeric genes in Ewing's sarcoma and its clinical applications. Biol Pharm Bull. 2002; 25: 991-994.